Madrigal Pharmaceuticals Inc (NAS:MDGL)
$ 318.55 -9.64 (-2.94%) Market Cap: 6.95 Bil Enterprise Value: 6.28 Bil PE Ratio: 0 PB Ratio: 8.94 GF Score: 42/100

Madrigal Pharmaceuticals Inc Phase 3 MAESTRO-NASH Trial Investor Call Transcript

Jun 24, 2023 / 04:30PM GMT
Paul A. Friedman
Madrigal Pharmaceuticals, Inc. - CEO & Director

So good evening, and thanks for joining Madrigal's EASL Investor Event and Webcast. With me today in Vienna are Dr. Becky Taub, President of R&D and Chief Medical Officer; and Dr. Stephen Harrison, lead investigator of our Phase III MISO studies of resmetirom. Fine print. These are our forward-looking statements. I'd ask you to see Thursday's press release and our recent SEC filings for risk factor considerations associated with these statements and our business. We'd like to express our thanks to EASL for selecting -- the pivotal Phase III MAESTRO-NASH trial of resmetirom is the first abstract to open Thursday general session of the Congress. The presentation signaled an important milestone for Madrigal and the Nash field. And based on the positive feedback and words of encouragement we received from thought leaders, community clinicians and our other stakeholders after the presentation. I believe that the MAESTRO-NASH data set the tone for the meeting.

Before Becky and Stephen Harrison review the detailed that, I'd like

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot